Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

Laboratory testing is a key component of models of care for all types of lipid disorders.  New therapies demand accuracy of dyslipidemia testing at very low LDL cholesterol concentration ranges.  Inaccurate results lead to incorrect diagnosis and therapeutic management, both of which are costly to society and harmful to patients. To address these key issues of lipoprotein and apolipoprotein markers and reach consensus on contemporary lipid testing, a multidisciplinary panel was established by the European Federation of Clinical Chemistry and Laboratory Medicine and the European Atherosclerosis Society.       The July 2018 issue of Clinical Chemistry includes a special report from this joint consensus initiative.  It provides recommendations for improving the use of the lipid profile to assess cardiovascular disease risk conferred by atherogenic lipoproteins.